The research progress of Hepatitis C vaccine
YAO Min;LI Shilin;CHEN Limin;Institute of Blood Transfusion,Chinese Academy of Medical Sciences,Peking Union Medical College,Provincial Key Laboratory for Transfusion-Transmitted Diseases of Sichuan Province;
HCV( Hepatitis C) is a blood-borne liver disease caused by the hepatitis C virus( HCV) infection. Chronic infections may lead to chronic inflammation,necrosis and fibrosis of liver with potential to develop into cirrhosis and hepatocellular carcinoma. Hepatitis C is spread worldwide. According to the World Health Organization( WHO),there are approximately 130-150 million people currently infected with chronic hepatitis C in the world. In addition,the number of new infections is on the rise by 3,000,000-4,000,000 per year,and about 500,000 people died from end-stage liver diseases caused by HCV each year. The treatment regimen is mainly composed of pegylated-interferon alpha and ribavirin. Although directacting antiviral drugs( DAAs) show better efficacy,some patients still do not respond optimally and DAAs are very expensive. As such,developing HCV vaccine is urgently needed. Although no HCV vaccine is available in the clinic at present,tremendous progress has been made in the field. This review will focus on the current status of HCV vaccine development.